LFSC - ETF AI Analysis
Top Page
F/M Emerald Life Sciences Innovation ETF (LFSC)
LFSC’s rating reflects a mix of promising life sciences innovators alongside several high-risk, unprofitable biotech names. Strong holdings like United Therapeutics and Corcept Therapeutics, which show solid financial performance, positive earnings calls, and supportive technical trends, help lift the fund’s quality. However, weaker positions such as Cogent Biosciences and Spyre Therapeutics, which face ongoing losses, bearish momentum, and valuation challenges, weigh on the rating, and the fund’s concentration in early-stage biotech and life sciences companies is a key risk factor.
LFSC vs. SPDR S&P 500 ETF (SPY)
- AUM
- 125.43M
- Region
- North America
- Expense Ratio
- 0.54%
- Beta
- 1.07
- Issuer
- F/m
- Inception Date
- Oct 30, 2024
- Dividend Yield
- N/A
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
LFSC Summary
The F/M Emerald Life Sciences Innovation ETF (LFSC) focuses on innovative health care companies, especially in pharmaceuticals, biotechnology, and life sciences. It does not track a traditional index, but instead selects U.S. firms working on new drugs, medical treatments, and diagnostic tools. Well-known names in the fund include Guardant Health and United Therapeutics. Someone might invest in this ETF to seek growth from medical breakthroughs and to add specialized health care exposure to their portfolio. However, it is heavily concentrated in a single, high-risk sector, so its price can swing sharply up or down.
How much will it cost me?
This ETF has an expense ratio of 0.54%, which means you’ll pay about $5.40 per year for every $1,000 invested. That’s higher than the average low-cost index ETF because this fund is actively managed and focuses on a specialized niche in life sciences and biotech.
What would affect this ETF?
LFSC could benefit from ongoing medical breakthroughs, supportive health care policies, and strong demand for innovative treatments among its U.S. pharma and biotech holdings, which may boost growth for companies like Corcept Therapeutics and Guardant Health. On the downside, setbacks in drug trials, tighter regulations, changes in health care reimbursement, or rising interest rates that make riskier growth stocks less attractive could hurt the fund’s performance given its heavy concentration in life sciences and smaller, specialized firms.
LFSC Top 10 Holdings
LFSC is a pure play on U.S. life sciences, with a heavy tilt toward smaller, high‑beta biotech names. United Therapeutics and Corcept Therapeutics are the steadier engines, rising on solid revenue and profitability, helping anchor the fund. Guardant Health and LivaNova add to the upside with improving momentum, while still wrestling with financial and valuation questions. On the flip side, Cogent Biosciences and Travere Therapeutics are lagging, their losses and weak trends acting like sandbags on performance. Overall, this ETF leans into innovative, higher‑risk health care stories rather than defensive blue chips.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 REPL | Replimune Group | 8.66% | $10.86M | $1.67B | 71.80% | 42Neutral |
 LIVN | LivaNova | 6.88% | $8.62M | $4.35B | 49.59% | 63Neutral |
 COGT | Cogent Biosciences | 6.04% | $7.58M | $5.38B | 91.36% | 37Underperform |
 TVTX | Travere Therapeutics | 5.69% | $7.14M | $4.75B | 69.95% | 56Neutral |
 GH | Guardant Health | 5.61% | $7.04M | $23.99B | 93.49% | 61Neutral |
 BLLN | BillionToOne, Inc. Class A | 4.99% | $6.26M | $5.35B | 4.02% | ―― |
 CORT | Corcept Therapeutics | 4.76% | $5.97M | $8.77B | 12.26% | 76Outperform |
 MANE | Veradermics, Incorporated | 4.28% | $5.37M | $5.84B | 270.04% | ―― |
 SYRE | Spyre Therapeutics | 4.10% | $5.14M | $8.91B | 298.02% | 43Neutral |
 UTHR | United Therapeutics | 3.83% | $4.80M | $25.68B | 32.01% | 79Outperform |
LFSC Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For LFSC, the sentiment is Positive. The current price of 43.60 is above the 20-day moving average (MA) of 42.27, below the 50-day MA of 44.30, and above the 200-day MA of 40.59, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 52.44 is Neutral, neither overbought nor oversold. The STOCH value of 87.49 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LFSC.
LFSC Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| LFSC | $43.60 | $42.00(-3.66% Downside) | $125.43M | 0.54% | 51Neutral |
 GTOP | $46.82 | $63.15(34.87% Upside) | $707.62M | 0.65% | 73Outperform |
 FEPI | $38.58 | $54.31(40.77% Upside) | $717.23M | 0.65% | 71Outperform |
 IETC | $102.17 | $144.05(41.00% Upside) | $671.84M | 0.18% | 74Outperform |
 AIPI | $33.76 | $46.83(38.72% Upside) | $478.04M | 0.65% | 73Outperform |
 PINK | $40.62 | $50.37(24.00% Upside) | $335.60M | 0.51% | 65Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| LFSC | F/M Emerald Life Sciences Innovation ETF | 43.60 | 11.31 | 35.02% | |
| GTOP | Goldman Sachs Technology Opportunities ETF | 46.82 | 6.82 | 17.06% | |
| FEPI | REX FANG & Innovation Equity Premium Income ETF | 38.58 | 0.45 | 1.17% | |
| IETC | iShares Evolved US Technology ETF | 102.17 | -5.31 | -4.94% | |
| AIPI | REX AI Equity Premium Income ETF | 33.76 | 2.21 | 7.01% | |
| PINK | Simplify Health Care ETF | 40.62 | 7.99 | 24.47% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.